|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/13/18 Nymox Pharmaceutical Corp 6-K 6/30/18 35:1.3M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 6-K Report by a Foreign Issuer HTML 17K
2: EX-99.1 Quarterly Report for the Quarter Ended HTML 212K
3: EX-99.2 CEO Certification HTML 19K
4: EX-99.3 CFO Certification HTML 19K
11: R1 Document and Entity Information HTML 37K
12: R2 Consolidated Statements of Operations (Unaudited) HTML 48K
13: R3 Consolidated Statements of Financial Position HTML 65K
14: R4 Consolidated Statements of Financial Position HTML 14K
(Parenthetical)
15: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 51K
16: R6 Consolidated Statement of Changes in Equity HTML 35K
(Unaudited)
17: R7 Basis of preparation HTML 18K
18: R8 Liquidity, Going Concern and Managements Response HTML 16K
19: R9 Share capital HTML 52K
20: R10 Earnings per share HTML 29K
21: R11 Related Party Transactions HTML 33K
22: R12 Subsequent events HTML 15K
23: R13 Share capital (Tables) HTML 57K
24: R14 Earnings per share (Tables) HTML 28K
25: R15 Related Party Transactions (Tables) HTML 29K
26: R16 Share capital (Details) HTML 31K
27: R17 Share capital (Details 1) HTML 20K
28: R18 Share capital (Details 2) HTML 17K
29: R19 Share Capital (Details Narrative) HTML 29K
30: R20 Earnings per share (Details) HTML 20K
31: R21 Related Party Transactions (Details) HTML 22K
32: R22 Related Party Transactions (Details Narrative) HTML 22K
34: XML IDEA XML File -- Filing Summary XML 54K
33: EXCEL IDEA Workbook of Financial Reports XLSX 25K
5: EX-101.INS XBRL Instance -- nymx-20180630 XML 381K
7: EX-101.CAL XBRL Calculations -- nymx-20180630_cal XML 66K
8: EX-101.DEF XBRL Definitions -- nymx-20180630_def XML 101K
9: EX-101.LAB XBRL Labels -- nymx-20180630_lab XML 287K
10: EX-101.PRE XBRL Presentations -- nymx-20180630_pre XML 209K
6: EX-101.SCH XBRL Schema -- nymx-20180630 XSD 109K
35: ZIP XBRL Zipped Folder -- 0001640334-18-001545-xbrl Zip 37K
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the period ended June 30, 2018
Commission File Number: 001-12033
| Nymox Pharmaceutical Corporation |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ¨
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____________
| Exhibits | |
|
| |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| |||
| NYMOX PHARMACEUTICAL CORPORATION |
| ||
| (Registrant) | |||
|
| |||
| By: | |||
|
| |||
|
| President and Chief Executive Officer | ||
Date: August 10, 2018
| 3 |
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/13/18 | None on these Dates | ||
| 8/10/18 | ||||
| For Period end: | 6/30/18 | |||
| List all Filings | ||||